Confident Investing Starts Here:
- Quickly and easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter
Precision BioSciences ( (DTIL) ) has provided an announcement.
On May 15, 2025, Precision BioSciences reported its first quarter financial results and provided a business update, highlighting new clinical data for its ARCUS-based programs. The company announced progress in its ELIMINATE-B trial for PBGENE-HBV, a potential curative treatment for chronic Hepatitis B, which received Fast Track Designation from the FDA. Additionally, Precision is accelerating its PBGENE-DMD program for Duchenne’s Muscular Dystrophy, aiming to file an IND/CTA in 2025, with clinical data expected in 2026. The company plans to pause the development of PBGENE-3243 to focus resources on these programs.
The most recent analyst rating on (DTIL) stock is a Buy with a $60.00 price target. To see the full list of analyst forecasts on Precision BioSciences stock, see the DTIL Stock Forecast page.
Spark’s Take on DTIL Stock
According to Spark, TipRanks’ AI Analyst, DTIL is a Neutral.
Precision BioSciences shows promising revenue growth and low debt levels, contributing to a stable financial position. However, profitability and cash flow challenges weigh on its financial performance. The technical analysis suggests potential short-term upward momentum, but the stock remains below its 200-day moving average, indicating caution for long-term trends. The valuation is attractive with a low P/E ratio, suggesting the stock might be undervalued. The corporate event of accelerating the PBGENE-DMD program adds positive future potential. Overall, while there are promising indicators, significant focus on improving cash flow and profitability is needed for a more favorable outlook.
To see Spark’s full report on DTIL stock, click here.
More about Precision BioSciences
Precision BioSciences, Inc. is a clinical-stage gene editing company that utilizes its proprietary ARCUS platform to develop in vivo gene editing therapies for diseases with high unmet needs.
Average Trading Volume: 156,760
Technical Sentiment Signal: Sell
Current Market Cap: $54.28M
Find detailed analytics on DTIL stock on TipRanks’ Stock Analysis page.